TSE:4527Personal Products
Rohto Pharmaceutical (TSE:4527) Margin Softness Challenges Long Running Earnings Growth Narrative
Rohto PharmaceuticalLtd (TSE:4527) has just wrapped up FY 2026 with Q4 revenue of ¥90.7b and basic EPS of ¥26.41, set against trailing twelve month revenue of ¥343.7b and EPS of ¥151.56 that investors have been tracking closely. Over recent periods the company has seen quarterly revenues move from ¥88.8b in Q3 FY 2026 to ¥90.7b in Q4, while basic EPS has ranged from ¥52.08 in Q1 to ¥26.41 in Q4, providing a view of how top line and EPS have been pacing through the year. With a trailing net...